216 related articles for article (PubMed ID: 18623899)
61. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
62. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
63. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
64. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
[TBL] [Abstract][Full Text] [Related]
65. [Acute lymphoblastic leukemia in elderly: prognosis and treatment].
Thomas X; Tavernier E; Le QH
Bull Cancer; 2004 Sep; 91(9):713-20. PubMed ID: 15544997
[TBL] [Abstract][Full Text] [Related]
66. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
67. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
68. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
69. A report of three patients treated with immunocell therapy with imatinib mesylate.
Kaneko T; Goto S; Kushima Y; Miyamoto Y; Eriguchi M; Nieda M; Egawa K
Anticancer Res; 2004; 24(5C):3303-9. PubMed ID: 15515425
[TBL] [Abstract][Full Text] [Related]
70. Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
Costa LJ
Br J Haematol; 2009 Sep; 146(5):576-7. PubMed ID: 19555375
[No Abstract] [Full Text] [Related]
71. [Acute lymphoblastic leukemia (ALL)].
Imai K; Akiyama H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2180-4. PubMed ID: 18079617
[TBL] [Abstract][Full Text] [Related]
72. Livedoid skin reaction probably due to imatinib therapy.
Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
[TBL] [Abstract][Full Text] [Related]
73. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
74. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
75. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
76. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
Van Glabbeke M; Verweij J; Casali PG; Simes J; Le Cesne A; Reichardt P; Issels R; Judson IR; van Oosterom AT; Blay JY
Eur J Cancer; 2006 Sep; 42(14):2277-85. PubMed ID: 16876399
[TBL] [Abstract][Full Text] [Related]
77. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
Price VE; Fletcher JA; Zielenska M; Cole W; Viero S; Manson DE; Stuart M; Pappo AS
Pediatr Blood Cancer; 2005 May; 44(5):511-5. PubMed ID: 15503291
[TBL] [Abstract][Full Text] [Related]
78. Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia?
Köchling J; Schmidt M; Rott Y; Sagner M; Ungefroren H; Wittig B; Henze G
Eur J Haematol; 2013 Apr; 90(4):291-300. PubMed ID: 23294316
[TBL] [Abstract][Full Text] [Related]
79. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
Wassmann B
Drugs; 2007; 67(17):2656. PubMed ID: 18034598
[No Abstract] [Full Text] [Related]
80. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
Fava P; Stroppiana E; Savoia P; Bernengo MG
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
